A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs ADX 102 (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Aldeyra Therapeutics
- 08 Aug 2017 According to an Aldeyra Therapeutics media release, data from this trial are expected in September 2017.
- 18 Jul 2017 According to an Aldeyra Therapeutics media release, last patient has been dosed.
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting,according to an Aldeyra Therapeutics media release.